Hallmarks of senescence in carcinogenesis and cancer therapy
The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Abstract
Cellular senescence is a signal transduction program leading to irreversible cell cycle arrest. This growth arrest can be triggered by many different mechanisms including recognition by cellular sensors of DNA double-strand breaks leading to the activation of cell cycle checkpoint responses and recruitment of DNA repair foci. Senescence is initiated by the shortening of telomeres (replicative senescence) or by other endogenous and exogenous acute and chronic stress signals (STASIS: stress or aberrant signaling-induced senescence). The process of carcinogenesis involves a series of changes that allow tumor cells to bypass the senescence program. Nevertheless, tumor cells retain the capacity to undergo senescence. Treatment of tumor cells with many conventional anticancer therapies activates DNA damage signaling pathways, which induce apoptosis in some cells and senescence in others. Overexpression of tumor suppressors or inhibition of oncogenes can also induce rapid senescence in tumor cells. Senescent cells, while not dividing, remain metabolically active and produce many secreted factors, some of which stimulate and others inhibit the growth of tumors. The emerging knowledge about the pathways that lead to senescence and determine the pattern of gene expression in senescent cells may lead to more effective treatments for cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, some tumor cells retain the ability to senesce in response to DNA-damaging chemotherapy or p53 reactivation; in mice, this response arrests tumor progression [ 20 – 22 ].”
From Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor (2008) · cites this paper as [20]
Citations
Cites
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508 · cited 1×
“When some telomeres are short, cells undergo a growth arrest called replicative senescence (Hayflick and Moorhead, 1961; Harley et al., 1990; Shay and Wright, 2001).”
BackgroundA biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477 · cited 2×
“Also, as in the case of replicative senescence, these cells remain metabolically and synthetically active and show characteristic changes in morphology (Dimri et al., 1995; Serrano et al., 1997; Drayton and Peters, 2002).”
BackgroundSpecific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 2×
“Telomerase activity is present in almost all human tumors but not in adjacent normal cells (Kim et al., 1994; Shay and Bacchetti, 1997).”
BackgroundSelf-citationTelomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750 · cited 3×
“When some telomeres are short, cells undergo a growth arrest called replicative senescence (Hayflick and Moorhead, 1961; Harley et al., 1990; Shay and Wright, 2001).”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 3×
“Also, as in the case of replicative senescence, these cells remain metabolically and synthetically active and show characteristic changes in morphology (Dimri et al., 1995; Serrano et al., 1997; Drayton and Peters, 2002).”
BackgroundExtension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
Self-citationIdentification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400 · cited 1×
“Telomerase is a eukaryotic ribonucleoprotein complex (Greider and Blackburn, 1985; Morin, 1989; Blackburn, 1992; Lingner et al., 1997; Nakamura et al., 1997; Weinrich et al., 1997; Nugent and Lundblad, 1998; Bryan and Cech, 1999) that helps to stabilize telomere length in human stem cells,…”
BackgroundA DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917 · cited 2×
“It has recently been shown that DNA damage signals from telomeres induce typical DNA damage foci containing factors such as g-H2AX, MRE11, NBS1, MDC1, 53BP1, RAD50, and BRCA1 at M1 senescence (di Fagagna et al., 2003).”
BackgroundA survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794
Self-citationMammalian Telomeres End in a Large Duplex Loop
Griffith, J. D., Comeau, L., Rosenfield, S., Stansel, R. M., Bianchi, A., Moss, H., & de Lange, T. (1999) · Cell · doi:10.1016/s0092-8674(00)80760-6 · Cited by 2,447 · cited 1×
“…repetitive TTAGGG tracts followed by a single-strand overhang on the 30 G-rich strand that ends in a lariat-like structure called a t-loop (Blackburn and Gall, 1978; Cooke and Smith, 1986; Moyzis et al., 1988; Chong et al., 1995; Broccoli et al., 1997; Griffith et al., 1999; Stansel et al., 2001).”
Background
Research works printed but not linked: 2
- Roninson IB and Dokmanovic M . (2002). J. Cell Biochem., 1–12. · DOI · Paper page
- Wright WE and Shay JW . (1996). In Modern Cell Biology Series, Holbrook NJ, Martin GR (eds) Wiley–Liss Inc.: New York, pp 153–167.
Cited by
Cellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Self-citationFour faces of cellular senescence
Rodier, F., & Campisi, J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009094 · Cited by 2,070
“In addition, some tumor cells retain the ability to senesce (Shay and Roninson, 2004), and do so in vivo in response to chemotherapy (Schmitt et al.”
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
“In this case, they would be likely to remai n dormant 151 permanently, as replicative senescence is generally believed to be irrever s bl [16].”
Metadata
- Authors
- Shay, J. W., & Roninson, I. B.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Roninson, Igor B
- Venue
- Oncogene
- Published
- 2004-04-12
- Volume
- 23
- Issue
- 16
- Pages
- 2919-2933
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2062107951
- Semantic Scholar
- bbc4d783cfd91b0ed59075622e40a9d18c5e0879
- Cited by
- 502
- References
- 150
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 14 · 2023: 6 · 2022: 10 · 2021: 14 · 2020: 15 · 2019: 12 · 2018: 16 · 2017: 20 · 2016: 29 · 2015: 36 · 2014: 31 · 2013: 27 · 2012: 28
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG017921, R01AG007992)
- National Cancer Institute (R01CA089636, P50CA070907, R01CA062099)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- cellular senescence, carcinogenesis, cancer therapy, replicative senescence, telomere shortening, Stasi, DNA double-strand breaks, cell cycle checkpoints, DNA repair, senescence-associated secretory phenotype, tumor suppressor, oncogenes, DNA damage signaling, apoptosis
- MeSH terms
- Animals, DNA Repair, Histones, Humans, Neoplasms, Retinoids, Signal Transduction, Gene Expression Regulation, Neoplastic, Telomere, Cellular Senescence, Telomerase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hallmarks of senescence in carcinogenesis and cancer therapy. https://app.cochat.ai/papers/10.1038/sj.onc.1207518
- The paper
- Shay, J. W., & Roninson, I. B. (2004). Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene. https://doi.org/10.1038/sj.onc.1207518
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.